Tatiana V. Dubinina
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Tatiana V. Dubinina has a total of 234 co-authors. Here are the top co-authors by number of shared publications:
- Aleksander M. Lila
V.A. Nasonova Research Institute of Rheumatology; Russian Medical Academy of Continuous Professional Education of the Ministry of Healthcare of the Russian Federation
20 shared publications - Sh. F. Erdes
V.A. Nasonova Research Institute of Rheumatology
20 shared publications - Anastasia B. Demina
V.A. Nasonova Research Institute of Rheumatology
18 shared publications - Ekaterina M. Agafonova
V.A. Nasonova Research Institute of Rheumatology
18 shared publications - Ekaterina V. Ilinykh
V.A. Nasonova Research Institute of Rheumatology
14 shared publications - Tatiana V. Korotaeva
V.A. Nasonova Research Institute of Rheumatology
14 shared publications
Latest Publications
- Open Access
- 31 October 2026
- Published by Mediar Press in Rheumatology Science and Practice
- Vol. 64 (5) , 548-552
Hip joint condition before total hip arthroplasty in patients with inflammatory rheumatic diseases who had not previously received or had received biological therapy
Aim : To conduct a comparative analysis of the state of the hip joint before total hip arthroplasty (THA) in patients with rheumatoid arthritis and ankylosing spondylitis who had not previously received and had received biological drugs. Materials and methods . The retrospective study included 458 patients (170 with ankylosing spondylitis and 288 with rheumatoid arthritis). Among the patients with ankylosing spondylitis, there were predominantly men (80.6%), and in rheumatoid arthritis – women (84.4%). The mean age was 38.1±11.3 and 42.4±9.6 years, respectively. The duration of hip pain before THA in patients with ankylosing spondylitis was 7.4±4.8 years, and in patients with rheumatoid arthritis – 5.6±3.2 years. Preoperative functional state of the hip was assessed using the modified Harris Hip Score, and macroscopic changes in the femoral heads and acetabulum were assessed intraoperatively. The participants were divided into two groups: group 1 – bio-naive patients (n=371) and group 2 – those with experience of biological drugs (n=87). Results. Preoperative assessment of the overall Harris Hip Score revealed worse hip joint function in the bio-naive group. Patients in this group also reported significantly higher hip pain levels, as assessed by the Harris Hip Score and visual analog scale. Objective assessment of hip motion by the physician revealed similar levels of functional limitations in these joints in both groups. Intraoperative assessment of the acetabulum also revealed no significant differences between the groups. Bio-naive patients were less likely to have partial absence of articular cartilage on the femoral head and joint ankylosis, and more likely to have chondromalacia. Conclusion . Patients using biologic drugs have better functional status of the hip joint than biologic-naive patients, which opens up prospects for increasing rehabilitation potential and reducing the recovery period after surgery.
- 31 October 2026
- Published by Mediar Press in Rheumatology Science and Practice
- Vol. 64 (5) , 548-552
Open AccessHip joint condition before total hip arthroplasty in patients with inflammatory rheumatic diseases who had not previously received or had received biological therapy
Aim : To conduct a comparative analysis of the state of the hip joint before total hip arthroplasty (THA) in patients with rheumatoid arthritis and ankylosing spondylitis who had not previously received and had received biological drugs. Materials and methods . The retrospective study included 458 patients (170 with ankylosing spondylitis and 288 with rheumatoid arthritis). Among the patients with ankylosing spondylitis, there were predominantly men (80.6%), and in rheumatoid arthritis – women (84.4%). The mean age was 38.1±11.3 and 42.4±9.6 years, respectively. The duration of hip pain before THA in patients with ankylosing spondylitis was 7.4±4.8 years, and in patients with rheumatoid arthritis – 5.6±3.2 years. Preoperative functional state of the hip was assessed using the modified Harris Hip Score, and macroscopic changes in the femoral heads and acetabulum were assessed intraoperatively. The participants were divided into two groups: group 1 – bio-naive patients (n=371) and group 2 – those with experience of biological drugs (n=87). Results. Preoperative assessment of the overall Harris Hip Score revealed worse hip joint function in the bio-naive group. Patients in this group also reported significantly higher hip pain levels, as assessed by the Harris Hip Score and visual analog scale. Objective assessment of hip motion by the physician revealed similar levels of functional limitations in these joints in both groups. Intraoperative assessment of the acetabulum also revealed no significant differences between the groups. Bio-naive patients were less likely to have partial absence of articular cartilage on the femoral head and joint ankylosis, and more likely to have chondromalacia. Conclusion . Patients using biologic drugs have better functional status of the hip joint than biologic-naive patients, which opens up prospects for increasing rehabilitation potential and reducing the recovery period after surgery.
- Open Access
- 30 August 2026
- Published by Mediar Press in Rheumatology Science and Practice
- Vol. 64 (4) , 406-414
Analysis of clinical and laboratory parameters affecting testosterone dynamics in men with ankylosing spondylitis and psoriatic arthritis: Results of a pilot observational study
Men with spondyloarthritis (SpA) are characterized by a high incidence of hypogonadism (low testosterone levels). Hypogonadism is associated with higher indicators of systemic inflammation and metabolic disorders. The aim – to compare the dynamics of spondyloarthritis activity with changes in total testosterone (TT) levels in men with ankylosing spondylitis (AS) and psoriatic arthritis (PsA). Materials and methods . Thirty-six men with AS and 47 men with PsA were included. All patients had their TT levels measured at baseline and during follow-up (on average, after 14.5 [12.8; 17.3] months for AS and 14.0 [9.5; 19.0] months for PsA). Subgroups were identified based on the presence/absence of decreased BASDAI (Bath Ankylosing Spondylitis Disease Activity Index) and DAPSA (Disease Activity in Psoriatic Arthritis) indices, as well as C-reactive protein (CRP) levels. A comparative assessment of quantitative and qualitative indicators reflecting the clinical features of AS and PsA was conducted at baseline and over time, as well as a correlation analysis between the studied quantitative indicators over time. Results. An inverse correlation was found between changes in testosterone levels and CRP (ρ=–0.4; p=0.015) in patients with AS. In PsA, no significant correlations were found between changes in TT levels and changes in indicators reflecting activity. In patients with AS, with decreased BASDAI activity, no significant changes in TT levels were observed. At the same time, a decrease in CRP from 9.6 [2.7; 33.9] to 1.9 [0.65; 8.5] mg/L (pConclusion. In patients with AS, a decrease in CRP during treatment is accompanied by an increase in TT levels.
- 30 August 2026
- Published by Mediar Press in Rheumatology Science and Practice
- Vol. 64 (4) , 406-414
Open AccessAnalysis of clinical and laboratory parameters affecting testosterone dynamics in men with ankylosing spondylitis and psoriatic arthritis: Results of a pilot observational study
Men with spondyloarthritis (SpA) are characterized by a high incidence of hypogonadism (low testosterone levels). Hypogonadism is associated with higher indicators of systemic inflammation and metabolic disorders. The aim – to compare the dynamics of spondyloarthritis activity with changes in total testosterone (TT) levels in men with ankylosing spondylitis (AS) and psoriatic arthritis (PsA). Materials and methods . Thirty-six men with AS and 47 men with PsA were included. All patients had their TT levels measured at baseline and during follow-up (on average, after 14.5 [12.8; 17.3] months for AS and 14.0 [9.5; 19.0] months for PsA). Subgroups were identified based on the presence/absence of decreased BASDAI (Bath Ankylosing Spondylitis Disease Activity Index) and DAPSA (Disease Activity in Psoriatic Arthritis) indices, as well as C-reactive protein (CRP) levels. A comparative assessment of quantitative and qualitative indicators reflecting the clinical features of AS and PsA was conducted at baseline and over time, as well as a correlation analysis between the studied quantitative indicators over time. Results. An inverse correlation was found between changes in testosterone levels and CRP (ρ=–0.4; p=0.015) in patients with AS. In PsA, no significant correlations were found between changes in TT levels and changes in indicators reflecting activity. In patients with AS, with decreased BASDAI activity, no significant changes in TT levels were observed. At the same time, a decrease in CRP from 9.6 [2.7; 33.9] to 1.9 [0.65; 8.5] mg/L (pConclusion. In patients with AS, a decrease in CRP during treatment is accompanied by an increase in TT levels.
- Open Access
- 30 August 2026
- Published by Mediar Press in Rheumatology Science and Practice
- Vol. 64 (4) , 385-397
Long-term efficacy of netakimab in the treatment of radiographic axial spondyloarthritis: Results of a systematic review and simulated indirect comparisons
The aim – to compare the long-term efficacy of netakimab with other registered drugs in the Russian Federation to treat radiographic axial spondyloarthritis over a period of up to 3 years. Materials and methods . A systematic literature search was conducted in PubMed and Embase databases. 19 publications evaluating the results of 11 clinical trials were selected. The simulated treatment comparison method according to NICE DSU TSD 18 (National Institute for Health and Care Excellence Decision Support Unit Technical Support Document 18) recommendations was used for comparison. Age, sex, BASDAI (Bath Ankylosing Spondylitis Disease Activity Index), ASDAS (Ankylosing Spondylitis Disease Activity Score), C-reactive protein, disease duration since axial spondyloarthritis diagnosis, and HLA-B27 status were selected as confounding variables for adjustment. Results . Netakimab demonstrated superiority over all interleukin 17 and tumor necrosis factor α (TNF-α) inhibitors, as well as tofacitinib, on the main efficacy endpoints ASAS20 and ASAS40 (20% and 40% improvement according to the Assessment of SpondyloArthritis international Society criteria) over a period of up to 3 years. No superiority was detected compared to upadacitinib. Conclusion. Netakimab is one of the most superior therapeutic option among available biologics for long-term treatment of active axial spondyloarthritis. Using netakimab as the first-line or second-line therapy allows achieving treatment goals with the highest probability. The results are useful for evidence-based clinical decision-making when choosing biological therapy considering patient profile and can be used for planning treatment strategy after TNF-α inhibitor failure.
- 30 August 2026
- Published by Mediar Press in Rheumatology Science and Practice
- Vol. 64 (4) , 385-397
Open AccessLong-term efficacy of netakimab in the treatment of radiographic axial spondyloarthritis: Results of a systematic review and simulated indirect comparisons
The aim – to compare the long-term efficacy of netakimab with other registered drugs in the Russian Federation to treat radiographic axial spondyloarthritis over a period of up to 3 years. Materials and methods . A systematic literature search was conducted in PubMed and Embase databases. 19 publications evaluating the results of 11 clinical trials were selected. The simulated treatment comparison method according to NICE DSU TSD 18 (National Institute for Health and Care Excellence Decision Support Unit Technical Support Document 18) recommendations was used for comparison. Age, sex, BASDAI (Bath Ankylosing Spondylitis Disease Activity Index), ASDAS (Ankylosing Spondylitis Disease Activity Score), C-reactive protein, disease duration since axial spondyloarthritis diagnosis, and HLA-B27 status were selected as confounding variables for adjustment. Results . Netakimab demonstrated superiority over all interleukin 17 and tumor necrosis factor α (TNF-α) inhibitors, as well as tofacitinib, on the main efficacy endpoints ASAS20 and ASAS40 (20% and 40% improvement according to the Assessment of SpondyloArthritis international Society criteria) over a period of up to 3 years. No superiority was detected compared to upadacitinib. Conclusion. Netakimab is one of the most superior therapeutic option among available biologics for long-term treatment of active axial spondyloarthritis. Using netakimab as the first-line or second-line therapy allows achieving treatment goals with the highest probability. The results are useful for evidence-based clinical decision-making when choosing biological therapy considering patient profile and can be used for planning treatment strategy after TNF-α inhibitor failure.
- Open Access
- 17 August 2026
- Published by IMA Press, LLC in Modern Rheumatology Journal
- Vol. 20 (4) , 136-138
Resolution of the Second Forum of Rheumatology Administrators, May 23–24, 2026, supported by the V.A. Nasonova Research Institute of Rheumatology and the League of Eurasian Rheumatologists (LEAR)
On May 23–24, a Forum of Rheumatology Administrators was held in Samarkand with the participation of leading specialists in rheumatology and healthcare organization. The forum was devoted to current challenges facing rheumatology services in the Russian Federation. The chief rheumatologists of Kazakhstan and Uzbekistan, who have collaborated with colleagues from the Russian Federation for many years, participated in the forum. Issues related to the systemic transformation of rheumatology services were discussed, including effective patient routing, ensuring early diagnosis, and equal access to modern therapy regardless of the region of residence.
- 17 August 2026
- Published by IMA Press, LLC in Modern Rheumatology Journal
- Vol. 20 (4) , 136-138
Open AccessResolution of the Second Forum of Rheumatology Administrators, May 23–24, 2026, supported by the V.A. Nasonova Research Institute of Rheumatology and the League of Eurasian Rheumatologists (LEAR)
On May 23–24, a Forum of Rheumatology Administrators was held in Samarkand with the participation of leading specialists in rheumatology and healthcare organization. The forum was devoted to current challenges facing rheumatology services in the Russian Federation. The chief rheumatologists of Kazakhstan and Uzbekistan, who have collaborated with colleagues from the Russian Federation for many years, participated in the forum. Issues related to the systemic transformation of rheumatology services were discussed, including effective patient routing, ensuring early diagnosis, and equal access to modern therapy regardless of the region of residence.
- Open Access
- 17 August 2026
- Published by IMA Press, LLC in Modern Rheumatology Journal
- Vol. 20 (4) , 51-57
Development of a prognostic model of work disability in patients with axial spondyloarthritis and its application in real-world clinical practice
Objective: to develop a model for predicting work disability in patients with axial psoriatic arthritis (axPsA) and ankylosing spondylitis (AS). Material and methods . The study included 74 patients with psoriatic arthritis and spinal involvement (axPsA) who met the CASPAR criteria (2006), and 44 patients with AS who met the modified New York criteria for AS (1984). A standard rheumatological examination was performed, including determination of the tender and swollen joint counts (TJC/68 and SJC/66 for PsA or TJC/44 and SJC/44 for AS), serum CRP level (mg/L), DAPSA/ASDAS arthritis/spondylitis activity indices, physician global assessment of disease activity using a visual analog scale (VAS, mm) and a numerical rating scale (NRS), and patient global assessment of health, including disease activity according to BASDAI, pain intensity and disease activity according to NRS and VAS in mm, fatigue according to the FACIT-F scale, fibromyalgia according to the FiRST questionnaire, and work productivity according to the WPAI-SPH questionnaire, including hours missed due to illness according to the presenteeism scale. Multivariate stepwise discriminant analysis was performed to identify predictors of work disability. Results and discussion . Based on a combination of significant factors, the following prognostic model of work disability was developed: -1.868 × FACIT-F (1 – severe fatigue; 2 – fatigue; 3 – no fatigue) + 1.194 × CRP (mg/L) + 0.846 × question 5 of the FiRST questionnaire (0 – no; 1 – yes) + 0.08 × SJC. The Pwork disability value was calculated; a value -2.812 corresponds to 20% of working hours missed due to illness according to the presenteeism scale. At Pwork disability <-2.812, the patient is able to work, and the proportion of working hours missed due to illness is Conclusion . A prognostic model for assessing work disability has been developed. By taking significant factors into account, this model will enable physicians to adjust treatment in a timely manner and reduce the risk of further patient disability.
- 17 August 2026
- Published by IMA Press, LLC in Modern Rheumatology Journal
- Vol. 20 (4) , 51-57
Open AccessDevelopment of a prognostic model of work disability in patients with axial spondyloarthritis and its application in real-world clinical practice
Objective: to develop a model for predicting work disability in patients with axial psoriatic arthritis (axPsA) and ankylosing spondylitis (AS). Material and methods . The study included 74 patients with psoriatic arthritis and spinal involvement (axPsA) who met the CASPAR criteria (2006), and 44 patients with AS who met the modified New York criteria for AS (1984). A standard rheumatological examination was performed, including determination of the tender and swollen joint counts (TJC/68 and SJC/66 for PsA or TJC/44 and SJC/44 for AS), serum CRP level (mg/L), DAPSA/ASDAS arthritis/spondylitis activity indices, physician global assessment of disease activity using a visual analog scale (VAS, mm) and a numerical rating scale (NRS), and patient global assessment of health, including disease activity according to BASDAI, pain intensity and disease activity according to NRS and VAS in mm, fatigue according to the FACIT-F scale, fibromyalgia according to the FiRST questionnaire, and work productivity according to the WPAI-SPH questionnaire, including hours missed due to illness according to the presenteeism scale. Multivariate stepwise discriminant analysis was performed to identify predictors of work disability. Results and discussion . Based on a combination of significant factors, the following prognostic model of work disability was developed: -1.868 × FACIT-F (1 – severe fatigue; 2 – fatigue; 3 – no fatigue) + 1.194 × CRP (mg/L) + 0.846 × question 5 of the FiRST questionnaire (0 – no; 1 – yes) + 0.08 × SJC. The Pwork disability value was calculated; a value -2.812 corresponds to 20% of working hours missed due to illness according to the presenteeism scale. At Pwork disability <-2.812, the patient is able to work, and the proportion of working hours missed due to illness is Conclusion . A prognostic model for assessing work disability has been developed. By taking significant factors into account, this model will enable physicians to adjust treatment in a timely manner and reduce the risk of further patient disability.
- Open Access
- 17 August 2026
- Published by IMA Press, LLC in Modern Rheumatology Journal
- Vol. 20 (4) , 132-135
Resolution of the Expert Council “Reproductive health of patients with rheumatic diseases during targeted therapy: from preconception preparation to postpartum follow-up”
On June 19, 2026, a meeting of the Expert Council was held to discuss reproductive health issues in patients with immune-mediated inflammatory rheumatic diseases and the safety of antirheumatic therapy. Rheumatologists, obstetrician-gynecologists, reproductive medicine specialists, and other experts participated in the discussion.
- 17 August 2026
- Published by IMA Press, LLC in Modern Rheumatology Journal
- Vol. 20 (4) , 132-135
Open AccessResolution of the Expert Council “Reproductive health of patients with rheumatic diseases during targeted therapy: from preconception preparation to postpartum follow-up”
On June 19, 2026, a meeting of the Expert Council was held to discuss reproductive health issues in patients with immune-mediated inflammatory rheumatic diseases and the safety of antirheumatic therapy. Rheumatologists, obstetrician-gynecologists, reproductive medicine specialists, and other experts participated in the discussion.
- Open Access
- 17 August 2026
- Published by IMA Press, LLC in Modern Rheumatology Journal
- Vol. 20 (4) , 15-23
Non-interventional multicenter study of the management of patients with non-radiographic axial spondyloarthritis in real-world clinical practice in the Russian Federation (NiSpAR): data from the prospective part
In the Russian Federation, there is an unmet need for research of non-radiographic (nr) axial spondyloarthritis (nr-axSpA). Therefore, the noninterventional multicenter NiSpAR study was initiated in 2022. Objective: to describe a cohort of patients with nr-axSpA and approaches to its diagnosis in the Russian Federation. Material and methods . The study involved 20 research centers from different regions of the Russian Federation. The article presents the results of prospective follow-up. Of 272 screened patients with a preliminary diagnosis of nr-axSpA, 113 (41.5%) met the 2009 ASAS criteria. The mean age of the patients was 37.1±11.2 years, and the median disease duration was 17 [5; 60] months. The proportion of participants with a diagnosis duration of Results and discussion . Objective signs of inflammation were present in 85 (75.2%) patients; active sacroiliitis was detected by magnetic resonance imaging in 77 (68.1%), and elevated serum CRP levels were found in 40 (35.4%). During the 104 weeks of the study, a significant decrease in nr-axSpA activity according to the ASDAS and BASDAI indices was observed. Positive changes in CRP levels were noted, with the median decreasing 2.5-fold compared with baseline. The number of patients with very high nr-axSpA activity decreased almost 7-fold and that of patients with high activity decreased 1.7-fold; correspondingly, the proportion of patients with inactive disease increased, reaching a maximum of 60% at visit 3. The size of the group with low disease activity remained virtually unchanged by the end of follow-up. At the end of follow-up, radiographic axSpA/ankylosing spondylitis was diagnosed in 12 (10.6%) participants. The number of patients receiving bDMARDs increased to 14 (12.3%) by the end of the study. At baseline, physicians considered that 64.6% of patients required bDMARDs; this proportion was 20–30% by visit 2 and at subsequent visits. Conclusion . The results of the prospective stage of the study showed that, in real-world clinical practice, there is a continuing positive trend toward improved diagnosis of nr-axSpA, including its early forms with a duration of axial symptoms of up to 2 years. Treatment tactics are consistent with international standards. At the same time, there are limitations in prescribing bDMARDs and targeted synthetic DMARDs (tsDMARDs) to all patients who require them, which necessitates improved access to treatment in order to reduce the medical, social, and economic burden of axSpA in Russia.
- 17 August 2026
- Published by IMA Press, LLC in Modern Rheumatology Journal
- Vol. 20 (4) , 15-23
Open AccessNon-interventional multicenter study of the management of patients with non-radiographic axial spondyloarthritis in real-world clinical practice in the Russian Federation (NiSpAR): data from the prospective part
In the Russian Federation, there is an unmet need for research of non-radiographic (nr) axial spondyloarthritis (nr-axSpA). Therefore, the noninterventional multicenter NiSpAR study was initiated in 2022. Objective: to describe a cohort of patients with nr-axSpA and approaches to its diagnosis in the Russian Federation. Material and methods . The study involved 20 research centers from different regions of the Russian Federation. The article presents the results of prospective follow-up. Of 272 screened patients with a preliminary diagnosis of nr-axSpA, 113 (41.5%) met the 2009 ASAS criteria. The mean age of the patients was 37.1±11.2 years, and the median disease duration was 17 [5; 60] months. The proportion of participants with a diagnosis duration of Results and discussion . Objective signs of inflammation were present in 85 (75.2%) patients; active sacroiliitis was detected by magnetic resonance imaging in 77 (68.1%), and elevated serum CRP levels were found in 40 (35.4%). During the 104 weeks of the study, a significant decrease in nr-axSpA activity according to the ASDAS and BASDAI indices was observed. Positive changes in CRP levels were noted, with the median decreasing 2.5-fold compared with baseline. The number of patients with very high nr-axSpA activity decreased almost 7-fold and that of patients with high activity decreased 1.7-fold; correspondingly, the proportion of patients with inactive disease increased, reaching a maximum of 60% at visit 3. The size of the group with low disease activity remained virtually unchanged by the end of follow-up. At the end of follow-up, radiographic axSpA/ankylosing spondylitis was diagnosed in 12 (10.6%) participants. The number of patients receiving bDMARDs increased to 14 (12.3%) by the end of the study. At baseline, physicians considered that 64.6% of patients required bDMARDs; this proportion was 20–30% by visit 2 and at subsequent visits. Conclusion . The results of the prospective stage of the study showed that, in real-world clinical practice, there is a continuing positive trend toward improved diagnosis of nr-axSpA, including its early forms with a duration of axial symptoms of up to 2 years. Treatment tactics are consistent with international standards. At the same time, there are limitations in prescribing bDMARDs and targeted synthetic DMARDs (tsDMARDs) to all patients who require them, which necessitates improved access to treatment in order to reduce the medical, social, and economic burden of axSpA in Russia.
- Open Access
- 13 June 2026
- Published by Consilium Medicum in Terapevticheskii arkhiv
- Vol. 98 (5) , 282-289
Combined comorbid pathology in axial spondyloarthritis
Aim. To analyze the frequency of combined comorbid pathology and its effect on clinical and instrumental characteristics in axial spondyloarthritis (SpA), including axial psoriatic arthritis. Materials and methods. 222 patients were included in the study: 108 with axial SpA, 114 with axial psoriatic arthritis. The average age was 40.9±12.4 years, and the duration of inflammatory back pain was 68±53.3 months. A standard rheumatological examination, X-ray of the cervical and lumbar spine, and pelvis were performed. The activity of spondylitis was determined by BASDAI and ASDAS-CRP. The patients were divided into 3 groups: 1st – without comorbid diseases (CD) – 66 (29.7%) patients, 2nd – with 1–2 CD – 78 (35.1%), 3rd – with ≥3 CD – 78 (35.1%). Results. The patients in 3rd group were older than in the other groups (in 1st group – 39±12.1 years, in 2nd – 39±11.2, in 3rd – 44.5±13.1; p1-3=0.039, p2-3=0.028), they had a higher level of Pain (in the 1st – 54.3±19.7 mm VAS, in the 2nd – 51.1±22.7, in the 3rd – 63.3±19.4; p=0.01 for all comparisons), the ASDAS-CRP value was higher than in the 1st group (in the 1st – 2.2±1.1, in the 2nd – 2.6±1.1, 3rd – 2.7±0.9; p1-3=0.01), syndesmophytes were more common in the cervical and/or lumbar spine, ankylosis of the faceted joints in the cervical spine (p 0.05). The results of the cluster analysis allowed us to group the features into 4 main clusters. The first cluster, in which the ASDAS-CRP and BASDAI indices were grouped, is combined, on the one hand, with a cluster with the presence of psoriasis, comorbidity (≥3), and structural changes in the spine, on the other hand, with other CD and extra-skeletal manifestations of SpA. Conclusion. The presence of a combination of CD was associated with higher activity of spondylitis, more common structural injuries of the spine. The choice of therapy, taking into account СD and extra-skeletal manifestations of SpA, should improve patient treatment outcomes.
- 13 June 2026
- Published by Consilium Medicum in Terapevticheskii arkhiv
- Vol. 98 (5) , 282-289
Open AccessCombined comorbid pathology in axial spondyloarthritis
Aim. To analyze the frequency of combined comorbid pathology and its effect on clinical and instrumental characteristics in axial spondyloarthritis (SpA), including axial psoriatic arthritis. Materials and methods. 222 patients were included in the study: 108 with axial SpA, 114 with axial psoriatic arthritis. The average age was 40.9±12.4 years, and the duration of inflammatory back pain was 68±53.3 months. A standard rheumatological examination, X-ray of the cervical and lumbar spine, and pelvis were performed. The activity of spondylitis was determined by BASDAI and ASDAS-CRP. The patients were divided into 3 groups: 1st – without comorbid diseases (CD) – 66 (29.7%) patients, 2nd – with 1–2 CD – 78 (35.1%), 3rd – with ≥3 CD – 78 (35.1%). Results. The patients in 3rd group were older than in the other groups (in 1st group – 39±12.1 years, in 2nd – 39±11.2, in 3rd – 44.5±13.1; p1-3=0.039, p2-3=0.028), they had a higher level of Pain (in the 1st – 54.3±19.7 mm VAS, in the 2nd – 51.1±22.7, in the 3rd – 63.3±19.4; p=0.01 for all comparisons), the ASDAS-CRP value was higher than in the 1st group (in the 1st – 2.2±1.1, in the 2nd – 2.6±1.1, 3rd – 2.7±0.9; p1-3=0.01), syndesmophytes were more common in the cervical and/or lumbar spine, ankylosis of the faceted joints in the cervical spine (p 0.05). The results of the cluster analysis allowed us to group the features into 4 main clusters. The first cluster, in which the ASDAS-CRP and BASDAI indices were grouped, is combined, on the one hand, with a cluster with the presence of psoriasis, comorbidity (≥3), and structural changes in the spine, on the other hand, with other CD and extra-skeletal manifestations of SpA. Conclusion. The presence of a combination of CD was associated with higher activity of spondylitis, more common structural injuries of the spine. The choice of therapy, taking into account СD and extra-skeletal manifestations of SpA, should improve patient treatment outcomes.
- Open Access
- 22 April 2026
- Published by IMA Press, LLC in Modern Rheumatology Journal
- Vol. 20 (2) , 61-67
Search for significant clinical and imaging criteria for the differential diagnosis of axial spondyloarthritis and axial psoriatic arthritis
Objective: to identify a set of criteria for the differential diagnosis of axial spondyloarthritis (axSpA) and axial psoriatic arthritis (axPsA). Material and methods. A total of 222 patients were examined: 108 with axSpA (Group 1) and 114 with axPsA (Group 2). Group 1 included patients meeting the axSpA criteria; Group 2 included patients with PsA who had axial involvement and met the CASPAR criteria. Axial involvement was diagnosed in the presence of radiographically definite (rd) sacroiliitis (SI), i.e., bilateral SI grade ≥II or unilateral SI grade ≥III, or active SI on magnetic resonance imaging, or ≥1 syndesmophyte in the cervical spine (C-spine) and/or lumbar spine. Inflammatory back pain (IBP) was defined according to the ASAS criteria. Radiographs of the hands and feet were performed. A multivariate analysis method was used (classification tree construction). Results and discussion. Patients with axPsA were characterized by onset of back pain after the age of 45 years, the presence of polyarthritis with a tender joint count >5 and a swollen joint count >3, dactylitis, skin and nail psoriasis, osteolysis, joint ankylosis, extra-articular bone proliferation, and multiple erosions. Distinctive features included syndesmophytes in the cervical spine, asymmetric, non-bridging, bulky syndesmophytes, spinal changes in the absence of SI, and the presence of rdSI that developed without IBP. Patients with axSpA were characterized by a younger age (Conclusion. Classification tree construction made it possible to determine that the differential diagnosis is based on features such as the presence or absence of psoriasis in combination with peripheral symptoms (joint swelling, severe arthralgia) and radiographic signs of osteolysis.
- 22 April 2026
- Published by IMA Press, LLC in Modern Rheumatology Journal
- Vol. 20 (2) , 61-67
Open AccessSearch for significant clinical and imaging criteria for the differential diagnosis of axial spondyloarthritis and axial psoriatic arthritis
Objective: to identify a set of criteria for the differential diagnosis of axial spondyloarthritis (axSpA) and axial psoriatic arthritis (axPsA). Material and methods. A total of 222 patients were examined: 108 with axSpA (Group 1) and 114 with axPsA (Group 2). Group 1 included patients meeting the axSpA criteria; Group 2 included patients with PsA who had axial involvement and met the CASPAR criteria. Axial involvement was diagnosed in the presence of radiographically definite (rd) sacroiliitis (SI), i.e., bilateral SI grade ≥II or unilateral SI grade ≥III, or active SI on magnetic resonance imaging, or ≥1 syndesmophyte in the cervical spine (C-spine) and/or lumbar spine. Inflammatory back pain (IBP) was defined according to the ASAS criteria. Radiographs of the hands and feet were performed. A multivariate analysis method was used (classification tree construction). Results and discussion. Patients with axPsA were characterized by onset of back pain after the age of 45 years, the presence of polyarthritis with a tender joint count >5 and a swollen joint count >3, dactylitis, skin and nail psoriasis, osteolysis, joint ankylosis, extra-articular bone proliferation, and multiple erosions. Distinctive features included syndesmophytes in the cervical spine, asymmetric, non-bridging, bulky syndesmophytes, spinal changes in the absence of SI, and the presence of rdSI that developed without IBP. Patients with axSpA were characterized by a younger age (Conclusion. Classification tree construction made it possible to determine that the differential diagnosis is based on features such as the presence or absence of psoriasis in combination with peripheral symptoms (joint swelling, severe arthralgia) and radiographic signs of osteolysis.
- Open Access
- 2 March 2026
- Published by Mediar Press in Rheumatology Science and Practice
- Vol. 64 (1) , 53-59
Features of coxitis in spondyloarthritis
According to an epidemiological study, hip joint involvement was detected in 12–56% of patients with axial spondyloarthritis (axSpA) in Russia. Data on the incidence of coxitis in patients with axial psoriatic arthritis (axPsA) are lacking. The aim of the study was to compare radiographic changes in the hip joints in patients with axial spondyloarthritis and axial psoriatic arthritis and to evaluate the relationship between coxitis and disease activity. Material and methods. The study included 222 patients with a mean age of 35.7±12.7 years. The first group included 108 patients who met the 2009 ASAS (Assessment of SpondyloArthritis International Society) criteria for axSpA or the 1984 criteria for ankylosing spondylitis (AS); The second group included 114 patients with axPsA who met the CASPAR (ClASsification for Psoriatic ARthritis) criteria. Signs of axial involvement in psoriatic arthritis (PsA) were determined using instrumental imaging methods. Diagnosis required the presence of radiologically reliable sacroiliitis (SI), i.e., bilateral stage ≥II or unilateral stage ≥III according to Kellgren, or active sacroiliitis according to magnetic resonance imaging. The presence of at least one syndesmophyte (paraspinal ossificate) in the cervical (CS) or lumbar (LS) spine, as well as ankylosis of the facet joints of the CS, were also taken into account. The mean age of disease onset was 26.3±20.3 years; HLA-B27 was detected in 54% of patients. The diagnosis of coxitis was established based on a pelvic X-ray and calculation of the Bath Ankylosing Spondylitis Radiology Hip Index (BASRI hip) for each joint. Results. Radiographic evidence of coxitis was detected in 52 of the 222 patients included in the study, including 22 patients with AS and 30 patients with axPsA. Patients with axPsA were older than those with axSpA (median age 32 years and 45 years, respectively; pConclusion. Radiographic coxitis was detected in 20% of patients with axSpA and 26% with axPsA. In previous studies, the incidence of radiographic coxitis in patients with psoriatic arthritis did not exceed 10%. According to our study, patients with axPsA had high clinical and laboratory indicators of disease activity, as well as significant functional impairment.
- 2 March 2026
- Published by Mediar Press in Rheumatology Science and Practice
- Vol. 64 (1) , 53-59
Open AccessFeatures of coxitis in spondyloarthritis
According to an epidemiological study, hip joint involvement was detected in 12–56% of patients with axial spondyloarthritis (axSpA) in Russia. Data on the incidence of coxitis in patients with axial psoriatic arthritis (axPsA) are lacking. The aim of the study was to compare radiographic changes in the hip joints in patients with axial spondyloarthritis and axial psoriatic arthritis and to evaluate the relationship between coxitis and disease activity. Material and methods. The study included 222 patients with a mean age of 35.7±12.7 years. The first group included 108 patients who met the 2009 ASAS (Assessment of SpondyloArthritis International Society) criteria for axSpA or the 1984 criteria for ankylosing spondylitis (AS); The second group included 114 patients with axPsA who met the CASPAR (ClASsification for Psoriatic ARthritis) criteria. Signs of axial involvement in psoriatic arthritis (PsA) were determined using instrumental imaging methods. Diagnosis required the presence of radiologically reliable sacroiliitis (SI), i.e., bilateral stage ≥II or unilateral stage ≥III according to Kellgren, or active sacroiliitis according to magnetic resonance imaging. The presence of at least one syndesmophyte (paraspinal ossificate) in the cervical (CS) or lumbar (LS) spine, as well as ankylosis of the facet joints of the CS, were also taken into account. The mean age of disease onset was 26.3±20.3 years; HLA-B27 was detected in 54% of patients. The diagnosis of coxitis was established based on a pelvic X-ray and calculation of the Bath Ankylosing Spondylitis Radiology Hip Index (BASRI hip) for each joint. Results. Radiographic evidence of coxitis was detected in 52 of the 222 patients included in the study, including 22 patients with AS and 30 patients with axPsA. Patients with axPsA were older than those with axSpA (median age 32 years and 45 years, respectively; pConclusion. Radiographic coxitis was detected in 20% of patients with axSpA and 26% with axPsA. In previous studies, the incidence of radiographic coxitis in patients with psoriatic arthritis did not exceed 10%. According to our study, patients with axPsA had high clinical and laboratory indicators of disease activity, as well as significant functional impairment.